TScan enters $30M upfront collaboration with Amgen to identify Crohn's disease T-cell targets

TScan Therapeutics, Inc.

TScan receives $30M upfront; eligible for over $500M in development and commercial milestone payments.
Amgen gains exclusive global rights to develop and commercialize therapeutics from discovered targets.
Amgen holds an option to expand the collaboration to include ulcerative colitis under predefined terms.
TScan also earns tiered single-digit royalties on net sales from any products developed.

item 1.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TScan Therapeutics, Inc. entered into Agreement with Amgen Inc. valued at $30 million (effective 2023-05-08).

Action: entry
Agreement: collaboration
Counterparty: Amgen Inc.
Value: $30 million
Effective: 2023-05-08

Exact text from the filing

On May 8, 2023, TScan Therapeutics, Inc. (“ TScan ” or the “ Company ”), entered into a Collaboration Agreement (the “ Agreement ”) with Amgen Inc. (“ Amgen ”) to identify antigens recognized by T cells in patients with Crohn’s disease utilizing the Company’s proprietary target discovery platform, TargetScan (“ TargetScan ”).

View on SEC.gov

Browse all material agreements →

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-139057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.